News

Ms Daniels, who is currently the COO for Anodyne, will fill the CEO role held by company founder, Mark Bidner. Mr Bidner will remain active with the company

Memory Pharmaceuticals has exercised its option to complete the third and final tranche following the achievement of a predefined milestone related to the Phase IIa trial of R3487/MEM

Mr Liu will focus on enhancing the operations of the key departments across the company, as well as working with other senior management in providing strategic guidance, implementation

Under the agreement, which will go into effect on February 1, 2009, Premier’s members, a network of approximately 2,000 hospitals and 53,000 healthcare facilities, will benefit from the

In addition to fast track designation, the FDA has granted Droxidopa orphan drug status for the treatment of symptomatic neurogenic orthostatic hypotension and subsequently awarded Chelsea a special

Under the collaboration, Corgenix’s AtherOx products will be included in studies conducted by BG Medicine to predict near-term risk of first myocardial infarction. Under the terms of the

The pilot study was prompted, in part, by clinical reports of the reduced incidence of hypertrophic scars and beneficial healing properties associated with Collagenase Santyl ointment. The study

The FDA-cleared immunohistochemistry (IHC) image analysis applications are intended to be used as an aid to pathologists in detecting and quantifying estrogen receptor (ER) and progesterone receptor (PR)

Michael Griffith, the company’s founder and CEO since 2005, has resigned in order to pursue other opportunities. Mr Tyson is the former COO, president and CEO of Valeant